תבנית:תרופה/פרוטופיק 0.03% - Protopic 0.03%
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | L04AA Selective immunosuppressants |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | ×¢××¨× - DERMAL |
| צ×רת ××× ×× | ×ש××, OINTMENT ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | -Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies.-Treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who are not adequately responsive to or are intolerant of conventional therapies.-Maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).
|
| ת×× ×ת:× ×ª×× × ×¡×/תר×פ×/פר×××פ××§ 0.03% - Protopic 0.03% | |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| פר×××פ××§ 0.03% ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | - |
|---|---|
| ××××¢ ×רשת | - |
| ×©× ××¦×¨× | LEO PHARMA A/S , DENMARK |
| ×©× ××¢× ×ר×ש×× | DEXCEL LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 11/2002. ר×ש××× ×ת×ר××: 02/2013 |
| ת×ר×× ×¢×××× ××ר×× | 15/05/19 |
ת××× ×ª ×ר×××
××£ ×× × ×צר ×¢× ××× ××× ×××××ר ת×× ×ת ×¢× ×¤×¨×× ×תר×פ×.
- ××£ ×תר×פ×: פר×××פ××§ 0.03% - Protopic 0.03%
- ××ר××¡× ××× ×ת ×©× ×¤×¨×× ×תר×פ×: × ××ª× ×ער×× ×ת ××£ ×תר××¤× ××¢××. ×××××× ×××××¤× ×ת:
{{תר×פ×/פר×××פ××§ 0.03% - Protopic 0.03%}}
×:
{{תר×פ×/פר×××פ××§ 0.03% - Protopic 0.03%
| ×©× ×פר××ר=×¢×¨× ××ש (××רס ×ת ××¢×¨× ×©×××× ××××ר)
}}
השינוי האחרון נעשה בֹ־7 באפריל 2023 ב־16:36